U.S. markets open in 29 minutes
  • S&P Futures

    4,244.75
    -1.00 (-0.02%)
     
  • Dow Futures

    34,424.00
    -38.00 (-0.11%)
     
  • Nasdaq Futures

    14,016.00
    +21.75 (+0.16%)
     
  • Russell 2000 Futures

    2,335.50
    +1.60 (+0.07%)
     
  • Crude Oil

    71.74
    +0.83 (+1.17%)
     
  • Gold

    1,847.20
    -32.40 (-1.72%)
     
  • Silver

    27.61
    -0.54 (-1.90%)
     
  • EUR/USD

    1.2121
    +0.0015 (+0.12%)
     
  • 10-Yr Bond

    1.4650
    +0.0030 (+0.21%)
     
  • Vix

    15.92
    -0.18 (-1.12%)
     
  • GBP/USD

    1.4111
    -0.0005 (-0.04%)
     
  • USD/JPY

    109.7750
    +0.1400 (+0.13%)
     
  • BTC-USD

    39,576.31
    +3,673.79 (+10.23%)
     
  • CMC Crypto 200

    983.20
    +41.39 (+4.39%)
     
  • FTSE 100

    7,143.49
    +9.43 (+0.13%)
     
  • Nikkei 225

    29,161.80
    +213.07 (+0.74%)
     

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of ChemoCentryx, Inc. (CCXI) on Behalf of Investors

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Law Offices of Howard G. Smith announces an investigation on behalf of ChemoCentryx, Inc. ("ChemoCentryx" or the "Company") (NASDAQ: CCXI) investors concerning the Company’s possible violations of federal securities laws.

ChemoCentryx is a biopharmaceutical company. Its lead drug candidate is avacopan, which is developed as a potential treatment for ANCA-associated vasculitis ("AAV").

On July 9, 2020, ChemoCentryx announced that it had filed its New Drug Application ("NDA") for avacopan to the U.S. Food and Drug Administration ("FDA") for the treatment of AAV.

On May 4, 2021, the FDA released a "Briefing Document" concerning the Company’s NDA for avacopan, stating that "[c]omplexities of the study design, as detailed in the briefing document, raise questions about the interpretability of the data to define a clinically meaningful benefit of avacopan and its role in the management of AAV." The FDA also noted that "several areas of concern [that] rais[ed] uncertainties about the interpretability of these data and the clinical meaningfulness of these results." The FDA also raised serious safety concerns with avacopan for the treatment of AAV.

On this news, the Company’s stock price fell $22.19 per share, or 45.45%, to close at $26.63 per share on May 4, 2021, thereby injuring investors.

If you purchased ChemoCentryx securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210506006121/en/

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com